Since the outbreak of the coronavirus-2019 (COVID-19) pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications such as deep vein thrombosis ([@bib1]), pulmonary embolism ([@bib2]), or microvascular thrombosis ([@bib3]). All these data suggest the existence of a hypercoagulable state in patients with COVID-19 disease ([@bib4]). This hypercoagulability induced by COVID-19 seems to be responsible for venous thromboembolic events but can also cause arterial complications.Learning Objectives•To recognize vascular complications among COVID-19 patients.•To demonstrate the presence of aortic thrombosis in patients with COVID-19 disease.

Observation {#sec1}
===========

This paper describes 4 cases of aortic thrombosis in patients admitted for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the authors' hospital in Mulhouse, France, between March 26 and April 12, 2020. Clinical characteristics and biological details are summarized in [Table 1](#tbl1){ref-type="table"} .Table 1Demographic, Clinical, Tomographic, and Biological CharacteristicsPatient \#1Patient \#2Patient \#3Patient \#4Demographic characteristics Age, yrs64687278 SexMMMM BMI, kg/m^2^23342735Clinical characteristics Cardiovascular risk factorsNoneHypertension, history of smoking, dyslipidemiaHypertension, diabetes, dyslipidemiaHypertension, history of smoking Medical historyDown syndromeCoronary artery disease, deep vein thrombosisCoronary artery disease, pacemaker, hyperthyroidism, depressionCardiac hypertrophy, pulmonary embolism, sleep apnea Treatment at homeNoneAspirin, perindopril, bisoprolol, pravastatinAspirin, ramipril, simvastatin, ivabradine, metformin, valproic acidIrbesartan, pravastatin, omeprazol Symptoms at disease onsetFever, cough, dyspneaFever, cough, diarrheaCough, diarrhea, anosmiaFever, cough, diarrhea Time from disease onset to thrombotic event, days1810288 Manifestation of thrombotic eventNoneAcute bilateral lower-limb ischemiaAcute ischemia of the right lower limbAbdominal pain (right renal infarction) DeathNoYesNoYesCT findings Degree of lung injury, %2025-5025-5025-50 Thrombotic localizationNonobstructive descending aortic thrombus formationObstructive abdominal aortic and bilateral iliac common arteries thrombosisNonobstructive abdominal aortic thrombosis and right iliac common artery thrombosisNonobstructive abdominal aortic thrombus formation and right renal artery thrombosisBiological characteristics at thrombosis diagnostic time RT-PCR SARS-CoV-2-positive, +++++ White-cell count, per mm^3^ (RV 4,000 to 11,000)15,4909,1506,06014,170 Total neutrophils, per mm^3^ (RV 2,100 to 8,900)12,6908,2204,76012,840 Total lymphocytes, per mm^3^ (RV 1,260 to 3,350)1,150490790770 Total monocytes, per mm^3^ (RV 250 to 840)1,160380450680 Platelet count, per mm^3^ (RV 150,000 to 450,000)172,000248,000115,000134,000 Hemoglobin, per g/l (RV 130 to 160)177166169108 Prothrombin time, s (RV 10.2 to 12.9)14.414.912.718.1 Fibrinogen, g/l (RV 2.13 to 4.22)3.003.803.027.70 D-dimer, mg/l (RV \<500)2,1601,6961,8254,169 High-sensitivity cardiac troponin I, pg/ml (RV \<45)5409,000ND\<45 Antiphospholipid antibodiesNDND\-- Antithrombin, % (RV 83 to 126)ND78%104%79% eGFR, ml/min/1.73 m^2^) (RV ≥90)49766163 C-reactive protein, mg/l (RV 0 to 3)16357132[^1]

Case 1 {#sec1.1}
------

The first patient was a 64-year-old male with a history of Down syndrome (without congenital heart disease) admitted for hypoxemic pneumonia. COVID-19 disease was confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test. Computed tomography (CT) results showed bilateral ground glass opacities (20% lung injury) and a nonobstructive descending aortic thrombus formation ([Figure 1](#fig1){ref-type="fig"} ). This patient was treated with therapeutic anticoagulation and presented no further complications. He was discharged home at day 6.Figure 1Computed Tomography Angiography of Patient \#1CT angiography of patient 1 shows a nonobstructive thrombus formation of descending aorta **(arrow)** in an axial view **(A)** and a sagittal view **(B).**

Case 2 {#sec1.2}
------

The second patient was a 68-year-old male with history of smoking, hypertension, coronary artery disease, and deep vein thrombosis ([Table 1](#tbl1){ref-type="table"}) who was admitted for acute bilateral lower limb ischemia. COVID-19 disease was confirmed by RT-PCR results. CT showed bilateral ground glass opacities (25% to 50% lung injury) as well as an obstructive thrombosis of the abdominal aorta and bilateral common iliac artery thromboses ([Figure 2](#fig2){ref-type="fig"} ). An axillobifemoral bypass was performed, followed by therapeutic anticoagulation with good initial results. The patient died 7 days after surgery from a major hemorrhage.Figure 2Computed Tomography Angiography of Patient \#2CT angiography of patient 2 shows an obstructive thrombosis of the abdominal aorta **(arrow)** in an axial view **(A)** and a coronal view **(B)**.

Case 3 {#sec1.3}
------

The third patient was a 72-year-old male with history of hypertension, diabetes, and coronary artery disease ([Table 1](#tbl1){ref-type="table"}) who was admitted for hypoxic pneumonia. COVID-19 disease was confirmed by RT-PCR results, and CT showed bilateral ground glass opacities (25% to 50% lung injury). On day 14 after admission, the patient experienced acute ischemia of the right lower limb, and CT showed a nonobstructive abdominal aortic thrombosis as well as an obstructive right common iliac artery thrombosis ([Figure 3](#fig3){ref-type="fig"} ). The patient was treated with therapeutic anticoagulation, and surgical thrombectomy was performed 7 days later with a good result.Figure 3Computed Tomography Angiography of Patient \#3CT angiography of patient 3 shows a nonobstructive abdominal aortic thrombosis and an obstructive right common iliac artery thrombosis **(arrow)** in an axial view **(A)** and a coronal view **(B)**.

Case 4 {#sec1.4}
------

The fourth patient was a 78-year-old male with a history of smoking, hypertension, cardiac hypertrophy, and pulmonary embolism ([Table 1](#tbl1){ref-type="table"}) who was admitted for hypoxic pneumonia. COVID-19 disease was confirmed by RT-PCR results, and CT showed bilateral ground glass opacities (25% to 50% lung injury). On day 7 after admission, the patient presented with abdominal pain. Abdominal CT showed a nonobstructive abdominal aortic thrombus formation and a right renal infarction consistent with a thrombosis of the right renal artery ([Figure 4](#fig4){ref-type="fig"} ). Therapeutic anticoagulation was started. The patient presented with a cerebral infarction 2 days later and died.Figure 4Computed Tomography Angiography of Patient \#4CT angiography of patient 4 shows a nonobstructive abdominal aortic thrombus formation **(arrow)** in an axial view **(A)** and a sagittal view **(B)** and a right renal artery thrombosis **(dashed arrow)** in sagittal view.

Discussion {#sec2}
==========

To the authors' knowledge, this is the first series of aortic thrombosis cases in COVID-19 patients to be published. Prognosis of patients hospitalized with COVID-19 disease is often determined by the extent of pulmonary lesions. However, vascular complications can also greatly affect outcome, as illustrated here. Many authors have recently demonstrated a strong link between COVID-19 infection and thromboembolism. The physiopathology has not yet been fully elucidated, but current data suggest the existence of a hypercoagulability state in patients with COVID-19 disease. A recent paper attributes this state "to excessive inflammation, platelet activation, endothelial dysfunction, and stasis" ([@bib5]). Others have suggested that formation and polymerization of fibrin are responsible for this hypercoagulability ([@bib6]). Therefore, recent recommendations insist on thromboprophylactic measures to prevent thromboembolism ([@bib4],[@bib7],[@bib8]).

A recent publication found evidence of the presence of virus in endothelial cells ([@bib9]). One explanation is that the angiotensin-converting enzyme 2 receptor that the virus uses to infect cells is widely expressed in endothelial cells. This causes endotheliitis, which could explain why COVID-19 patients seem prone to venous and arterial thrombosis. This paper ([@bib9]) also underlines the fact that patients predisposed to endothelial lesions (hypertension, male sex, smoking, diabetes) could be more prone to infection of the endothelium induced by the virus. This was the case with the present series of patients who were all male, 75% had hypertension, 50% had a history of smoking, and 50% had a history of coronary artery disease. On the other hand, 2 of the 4 patients also had a history of pulmonary embolism or deep vein thrombosis, suggesting an individual predisposition. Finally, outcomes in COVID-19 patients affected by arterial thrombosis seem to be severe, as 50% of these patients died.

All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Case Reports*[author instructions page](https://www.jaccsubmit-casereports.org/cgi-bin/main.plex?form_type=display_auth_instructions){#intref0010}.

[^1]: BMI = body mass index; CT = computed tomography; eGFR = estimated glomerular filtration rate; ND = not determined; RT-PCR = reverse-transcriptase polymerase chain reaction; RV = reference values; SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2.
